Trileaflet setback cuts AoTtech value
This article was originally published in Clinica
Scottish company AorTech has blamed unspecified "performance issues" that emerged during preclinical trials for delays in further trials of its novel biocompatible polyuretheane trileaflet heart valve, the New Valve. The hold-up, announced last week, wiped almost a third off the value of the Bellshill, Lanarkshire company as shares dropped to 21p ($0.30). Tests on the product, which AorTech hopes will give it a share of the $800m worldwide heart valve market, may take another four months to complete.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.